Your browser doesn't support javascript.
loading
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
Shen, Min; Asawa, Rosita; Zhang, Ya-Qin; Cunningham, Elizabeth; Sun, Hongmao; Tropsha, Alexander; Janzen, William P; Muratov, Eugene N; Capuzzi, Stephen J; Farag, Sherif; Jadhav, Ajit; Blatt, Julie; Simeonov, Anton; Martinez, Natalia J.
Affiliation
  • Shen M; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
  • Asawa R; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
  • Zhang YQ; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
  • Cunningham E; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
  • Sun H; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
  • Tropsha A; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Janzen WP; Epizyme, Inc., Cambridge, MA, USA.
  • Muratov EN; Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
  • Capuzzi SJ; Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
  • Farag S; Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
  • Jadhav A; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
  • Blatt J; Division of Pediatric Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.
  • Simeonov A; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Martinez NJ; National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Oncotarget ; 9(4): 4758-4772, 2018 Jan 12.
Article in En | MEDLINE | ID: mdl-29435139
ABSTRACT
Drug repurposing approaches have the potential advantage of facilitating rapid and cost-effective development of new therapies. Particularly, the repurposing of drugs with known safety profiles in children could bypass or streamline toxicity studies. We employed a phenotypic screening paradigm on a panel of well-characterized cell lines derived from pediatric solid tumors against a collection of ∼3,800 compounds spanning approved drugs and investigational agents. Specifically, we employed titration-based screening where compounds were tested at multiple concentrations for their effect on cell viability. Molecular and cellular target enrichment analysis indicated that numerous agents across different therapeutic categories and modes of action had an antiproliferative effect, notably antiparasitic/protozoal drugs with non-classic antineoplastic activity. Focusing on active compounds with dosing and safety information in children according to the Children's Pharmacy Collaborative database, we identified compounds with therapeutic potential through further validation using 3D tumor spheroid models. Moreover, we show that antiparasitic agents induce cell death via apoptosis induction. This study demonstrates that our screening platform enables the identification of chemical agents with cytotoxic activity in pediatric cancer cell lines of which many have known safety/toxicity profiles in children. These agents constitute attractive candidates for efficacy studies in pre-clinical models of pediatric solid tumors.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Screening_studies Language: En Journal: Oncotarget Year: 2018 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Screening_studies Language: En Journal: Oncotarget Year: 2018 Document type: Article Affiliation country: Estados Unidos